Skip to main content

Advertisement

SpringerLink
Log in

Epidemiology and Management of Candidiasis in Solid Organ Transplant Recipients

  • Epidemiology of Fungal Infections (T Chiller and JA Baddley, Section Editors)
  • Published:
Current Fungal Infection Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Invasive candidiasis (IC) is the leading cause of fungal infections in solid organ transplant recipients (SOT). In this article, we aim to review the epidemiology, risk factors, presentation, and management of IC in this population.

Recent Findings

Certain risk factors have been associated with IC in SOT recipients. Targeted antifungal prophylaxis for SOT recipients at the highest risk of infection is currently recommended although the choice and duration of antifungal agents remain controversial. Early diagnosis and monitoring of IC in SOT recipients are critical to achieve better outcomes and prevent serious complications. Non-culture-based diagnostic modalities have been introduced to aid in earlier and more accurate diagnosis.

Summary

The use of azoles for prophylaxis or treatment in SOT recipients allowed for selection of resistance and increased the incidence of non-albicans Candida. Drug–drug interactions, cost, and risk of resistance are to be considered when using more potent or newer antifungal agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Lortholary O, Dupont B. Antifungal prophylaxis during neutropenia and immunodeficiency. Clin Microbiol Rev. 1997;10(3):477–504.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Tavanti A, Lupetti A, Ghelardi E, Corsini V, Davini P, Filipponi F, et al. Molecular monitoring of Candida albicans infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis. 2001;20(8):544–53.

    Article  CAS  PubMed  Google Scholar 

  3. •• Green M. Introduction: infections in solid organ transplantation. Am J Transplant. 2013;13:3–8. This paper explains the risk factors in SOT recipients and different IFIs in different stages.

  4. Silveira FP, Husain S. Fungal infections in solid organ transplantation. Med Mycol. 2007;45(4):305–20.

    Article  PubMed  Google Scholar 

  5. Grossi P, Gasperina DD, Barchiesi F, Biancofiore G, Carafiello G, Gasperi AD, et al. Italian guidelines for diagnosis, prevention, and treatment of invasive fungal infections in solid organ transplant recipients. Transplant Proc. 2011;43(6):2463–71.

    Article  CAS  PubMed  Google Scholar 

  6. • Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among organ transplant recipients: results of the transplant‐associated infection surveillance network (TRANSNET). Clin Infect Dis. 2010;50(8):1101–11. This paper describes the results of 23 US transplant centers to determine transplant-associated infections.

  7. Patel R. Infections in recipients of kidney transplants. Infect Dis Clin N Am. 2001;15(3):901–52.

    Article  CAS  Google Scholar 

  8. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin N Am. 2003;17:113–34.

    Article  Google Scholar 

  9. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis. 1993;16(5):677–88.

    Article  CAS  PubMed  Google Scholar 

  10. Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infect Dis Clin N Am. 1995;9(4):1045–74.

    CAS  Google Scholar 

  11. Stelzmueller I, Lass-Floerl C, Geltner C, Graziadei I, Schneeberger S, Antretter H, et al. Zygomycosis and other rare filamentous fungal infections in solid organ transplant recipients. Transpl Int. 2008;21(6):534–46.

    Article  PubMed  Google Scholar 

  12. Minari A, Husni R, Avery R, Longworth D, Decamp M, Bertin M, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis. 2002;4(4):195–200.

    Article  CAS  PubMed  Google Scholar 

  13. Patterson J, Peters J, Calhoon J, Levine S, Anzueto A, Al-Abdely H, et al. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients. Transpl Infect Dis. 2000;2(1):22–8.

    Article  CAS  PubMed  Google Scholar 

  14. Trullas J, Cervera C, Benito N, Bellacasa JPDL, Agustí C, Rovira M, et al. Invasive pulmonary aspergillosis in solid organ and bone marrow transplant recipients. Transplant Proc. 2005;37(9):4091–3.

    Article  CAS  PubMed  Google Scholar 

  15. Iversen M, Burton C, Vand S, Skovfoged L, Milman N, Carlsen J, et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis. 2007;26:879–86.

    Article  CAS  PubMed  Google Scholar 

  16. Vilchez R, Shapiro R, Mccurry K, Kormos R, Abu-Elmagd K, Fung J, et al. Longitudinal study of cryptococcosis in adult solid-organ transplant recipients. Transpl Int. 2003;16(5):336–40.

    Article  PubMed  Google Scholar 

  17. Mueller N, Fishman J. Asymptomatic pulmonary cryptococcosis in solid organ transplantation: report of four cases and review of the literature. Transpl Infect Dis. 2003;5(3):140–3.

    Article  CAS  PubMed  Google Scholar 

  18. Pugliese F, Ruberto F, Cappannoli A, Perrella S, Bruno K, Martelli S, et al. Incidence of fungal infections in a solid organ recipients dedicated intensive care unit. Transplant Proc. 2007;39(6):2005–7.

    Article  CAS  PubMed  Google Scholar 

  19. •• Silveira FP, Kusne S. Candida infections in solid organ transplantation. Am J Transplant. 2013;13:220–7. An important paper reviewing the current guidelines in the diagnosis and treatment of IC in SOT recipients.

  20. Mizuta M, Blumberg EA. Impact of fungal infections on solid-organ transplant recipients. Clin Microbiol Newsl. 2005;27(16):123–6.

    Article  Google Scholar 

  21. Gavaldà J, Meije Y, Fortún J, Roilides E, Saliba F, Lortholary O, et al. Invasive fungal infections in solid organ transplant recipients. Clin Microbiol Infect. 2014;20:27–48.

    Article  PubMed  Google Scholar 

  22. Golas M, Netsvyetayeva I, Piskorska K, Sikora M, Jaworska-Zaremba M, Mierzwinska-Nastalska E, et al. Polymerase chain reaction melting profiles of Candida glabrata clinical isolates in solid organ transplant recipients in comparison to the other group of surgical patients. Transplant Proc. 2014;46(5):1366–70.

    Article  CAS  PubMed  Google Scholar 

  23. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital‐acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis. 2002;35(5):627–30.

    Article  CAS  PubMed  Google Scholar 

  24. Bissell M. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Yearb Pathol Lab Med. 2006;2006:285–6.

    Article  Google Scholar 

  25. Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman CA. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis. 2005;41(7):975–81.

    Article  PubMed  Google Scholar 

  26. Hadley S, Samore MH, Lewis WD, Jenkins RL, Karchmer AW, Hammer SM. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or Fk506 as primary immunosuppression. Transplantation. 1995;59(6):851–8.

    Article  CAS  PubMed  Google Scholar 

  27. • Hal SV, Marriott D, Chen S, Nguyen Q, Sorrell T, Ellis D, et al. Candidemia following solid organ transplantation in the era of antifungal prophylaxis: the Australian experience. Transpl Infect Dis. 2009;11(2):122–7. This is an Australian study reviewing the rates of IFIs risk factors, presentation, and outcomes in SOT recipients and the effect of antifungal prophylaxis.

  28. Hibberd PL, Rubin RH. Clinical aspects of fungal infection in organ transplant recipients. Clin Infect Dis. 1994;19:S33–S40.

    Article  PubMed  Google Scholar 

  29. Patel R, Portela D, Badley AD, Harmsen WS, Larson-Keller JJ, Ilstrup DM, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation. 1996;62(7):926–34.

    Article  CAS  PubMed  Google Scholar 

  30. Collins LA, Samore MH, Roberts MS, Luzzati R, Jenkins RL, Lewis WD, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis. 1994;170(3):644–52.

    Article  CAS  PubMed  Google Scholar 

  31. Benedetti E, Gruessner AC, Troppmann C, Papalois BE, Sutherland DE, Dunn DL, et al. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. J Am Coll Surg. 1996;183(4):307–16.

    CAS  PubMed  Google Scholar 

  32. Warnock DW. Fungal complications of transplantation: diagnosis, treatment and prevention. J Antimicrob Chemother. 1995;36:73–90.

    Article  CAS  PubMed  Google Scholar 

  33. Winston DJ, Emmanouilides C, Busuttil RW. Infections in liver transplant recipients. Clin Infect Dis. 1995;21(5):1077–91.

    Article  CAS  PubMed  Google Scholar 

  34. Patterson J. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis. 1999;1(4):229–36.

    Article  CAS  PubMed  Google Scholar 

  35. Marco F, Lockhart SR, Pfaller MA, Pujol C, Rangel-Frausto MS, Wiblin T, et al. Elucidating the origins of nosocomial infections with Candida albicans by DNA fingerprinting with the complex probe Ca3. J Clin Microbiol. 1999;37(9):2817–28.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Sanchez V, Vazquez JA, Barth-Jones D, Dembry L, Sobel JD, Zervos MJ. Nosocomial acquisition of Candida parapsilosis: an epidemiologic study. Am J Med. 1993;94(6):577–82.

    Article  CAS  PubMed  Google Scholar 

  37. Husain S, Alexander BD, Munoz P, Avery RK, Houston S, Pruett T, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-aspergillus mycelial fungi. Clin Infect Dis. 2003;37(2):221–9.

    Article  PubMed  Google Scholar 

  38. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998;338(24):1741–51.

    Article  CAS  PubMed  Google Scholar 

  39. Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev. 2010;23(2):253–73.

    Article  PubMed  PubMed Central  Google Scholar 

  40. • Sobel JD. The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia. Curr Infect Dis Rep. 2006;8(6):427–33. This paper reviews the importance of non-albicans Candida in IC.

  41. Shoham S, Marwaha S. Invasive fungal infections in the ICU. J Intensive Care Med. 2009;25:78–92.

    Article  PubMed  Google Scholar 

  42. Shoham S, Marr KA. Invasive fungal infections in solid organ transplant recipients. Future Microbiol. 2012;7(5):639–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Florescu D, Islam K, Grant W, Mercer D, Langnas A, Botha J, et al. Incidence and outcome of fungal infections in pediatric small bowel transplant recipients. Transpl Infect Dis. 2010;12(6):497–504.

    Article  CAS  PubMed  Google Scholar 

  44. Reid GE, Grim SA, Sankary H, Benedetti E, Oberholzer J, Clark NM. Early intra-abdominal infections associated with orthotopic liver transplantation. Transplantation. 2009;87(11):1706–11.

    Article  PubMed  Google Scholar 

  45. Said A, Safdar N, Lucey MR, Knechtle SJ, D’alessandro A, Musat A, et al. Infected bilomas in liver transplant recipients, incidence, risk factors and implications for prevention. Am J Transplant. 2004;4(4):574–82.

    Article  PubMed  Google Scholar 

  46. Safdar N, Said A, Lucey MR, Knechtle SJ, D’alessandro A, Musat A, et al. Infected bilomas in liver transplant recipients: clinical features, optimal management, and risk factors for mortality. Clin Infect Dis. 2004;39(4):517–25.

    Article  PubMed  Google Scholar 

  47. Nucci M, Anaissie E, Betts RF, Dupont BF, Wu C, Buell DN, et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis. 2010;51(3):295–303.

    Article  PubMed  Google Scholar 

  48. Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ. Lysis—centrifugation blood cultures in the detection of tissue-proven invasive candidiasis disseminated versus single-organ infection. Diagn Microbiol Infect Dis. 1993;17(2):103–9.

    Article  CAS  PubMed  Google Scholar 

  49. •• Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):409–17. The latest practice guidelines for the management of candidiasis in the US by the Infectious Diseases Society of America.

  50. Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the third European Conference on Infections in Leukemia. Crit Care. 2010;14(6):R222.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Yera H, Sendid B, Francois N, Camus D, Poulain D. Contribution of serological tests and blood culture to the early diagnosis of systemic candidiasis. Eur J Clin Microbiol Infect Dis. 2001;20(12):864–70.

    Article  CAS  PubMed  Google Scholar 

  52. Prella M, Bille J, Pugnale M, Duvoisin B, Cavassini M, Calandra T, et al. Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagn Microbiol Infect Dis. 2005;51(2):95–101.

    Article  CAS  PubMed  Google Scholar 

  53. Hachem RY, Kontoyiannis DP, Chemaly RF, Jiang Y, Reitzel R, Raad I. Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol. 2008;47(1):129–33.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Ellis M, Al-Ramadi B, Finkelman M, Hedstrom U, Kristensen J, Ali-Zadeh H, et al. Assessment of the clinical utility of serial beta-D-glucan concentrations in patients with persistent neutropenic fever. J Clin Microbiol. 2008;57(Pt 3):287–95.

    CAS  Google Scholar 

  55. Pickering JW, Sant HW, Bowles CAP, Roberts WL, Woods GL. Evaluation of a (1->3)- -D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2005;43(12):5957–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Kato A, Takita T, Furuhashi M, Takahashi T, Maruyama Y, Hishida A. Elevation of blood (1→3)-beta-D-glucan concentrations in hemodialysis patients. Nephron. 2001;89(1):15–9.

    Article  CAS  PubMed  Google Scholar 

  57. Usami M, Ohata A, Horiuchi T, Nagasawa K, Wakabayashi T, Tanaka S. Positive (13)-beta-d-glucan in blood components and release of (13)-beta-d-glucan from depth-type membrane filters for blood processing. Transfusion. 2002;42(9):1189–95.

    Article  CAS  PubMed  Google Scholar 

  58. Mennink-Kersten MA, Warris A, Verweij PE. 1,3-β-D-glucan in patients receiving intravenous amoxicillin–clavulanic acid. N Engl J Med. 2006;354(26):2834–5.

    Article  CAS  PubMed  Google Scholar 

  59. Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol. 2010;49(2):665–70.

    Article  PubMed  Google Scholar 

  60. Mcmullan R, Metwally L, Coyle PV, Hedderwick S, Mccloskey B, O’neill HJ, et al. A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin Infect Dis. 2008;46(6):890–6.

    Article  CAS  PubMed  Google Scholar 

  61. •• Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015;60(6):892–9. A multicenter trial that introduced a new technique using T2 magnetic resonance and PCR to amplify and detect Candida DNA.

  62. Powell HL, Sand CA, Rennie RP. Evaluation of CHROMagar Candida for presumptive identification of clinically important Candida species. Diagn Microbiol Infect Dis. 1998;32(3):201–4.

    Article  CAS  PubMed  Google Scholar 

  63. Wilson DA, Joyce MJ, Hall LS, Reller LB, Roberts GD, Hall GS, et al. Multicenter evaluation of a Candida albicans peptide nucleic acid fluorescent in situ hybridization probe for characterization of yeast isolates from blood cultures. J Clin Microbiol. 2005;43(6):2909–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Hall L, Febre KML, Deml SM, Wohlfiel SL, Wengenack NL. Evaluation of the yeast traffic light PNA FISH probes for identification of Candida species from positive blood cultures. J Clin Microbiol. 2012;50(4):1446–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Shibata A, Kaneko T, Makimura K, Onozaki M, Ogihara T, Shibata H, et al. Comparative study of ability for growth support and species differentiation by colony features on commercial chromogenic agar, Pourmedia Vi Candida and CHROMagar Candida. Nippon Ishinkin Gakkai Zasshi. 2008;49(1):33–8.

    Article  CAS  Google Scholar 

  66. Lockhart SR, Wagner D, Iqbal N, Pappas PG, Andes DR, Kauffman CA, et al. Comparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: transplant-associated infections surveillance network (TRANSNET), 2001 to 2006. J Clin Microbiol. 2011;49(7):2404–10.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl. 2006;12(5):850–8.

    Article  PubMed  Google Scholar 

  68. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev. 2004;(3):CD004291-1-CD004291-63.

  69. •• Winston D, Limaye A, Pelletier S, Safdar N, Morris M, Meneses K, et al. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am J Transplant. 2014;14(12):2758–64. A trial that showed that anidulafungin had similar efficacy as fluconazole for liver transplant recipients.

  70. Fortún J, Martín-Dávila P, Montejo M, Muñoz P, Cisneros JM, Ramos A, et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation. 2009;87(3):424–35.

    Article  PubMed  Google Scholar 

  71. Köse Ş, Türken M, Akkoçlu G, Karaca C, Senger S. Disseminated candidiasis developing during prophylaxis with fluconazole in a small-intestine transplant recipient. Prog Transplant. 2012;22(1):110–2.

    Article  PubMed  Google Scholar 

  72. Uzun O, Ascioglu S, Anaissie EJ, Rex JH. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis. 2001;32(12):1713–7.

    Article  CAS  PubMed  Google Scholar 

  73. Husain S, Tollemar J, Dominguez EA, Baumgarten K, Humar A, Paterson DL, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study1. Transplantation. 2003;75(12):2023–9.

    Article  PubMed  Google Scholar 

  74. Marik PE. Fungal infections in solid organ transplantation. Expert Opin Pharmacother. 2006;7(3):297–305.

    Article  PubMed  Google Scholar 

  75. Lipp H-P. Antifungal agents—clinical pharmacokinetics and drug interactions. Mycoses. 2008;51(s1):7–18.

    Article  CAS  PubMed  Google Scholar 

  76. Saad AH, Depestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26(12):1730–44.

    Article  CAS  PubMed  Google Scholar 

  77. Pappas PG, Kauffman CA, Andes D, Benjamin JDK, Calandra TF, Edwards JJE, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503–35.

    Article  CAS  PubMed  Google Scholar 

  78. El-Ebiary M, Torres A, Fábregas N, Bellacasa JPDL, González J, Ramirez J, et al. Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. Am J Respir Crit Care Med. 1997;156(2 Pt1):583–90.

    Article  CAS  PubMed  Google Scholar 

  79. Rello J, Esandi M-E, Diaz E, Mariscal D, Gallego M, Vallès J. The role of Candida sp isolated from bronchoscopic samples in nonneutropenic patients. Chest. 1998;114(1):146–9.

    Article  CAS  PubMed  Google Scholar 

  80. Wood GC, Mueller EW, Croce MA, Boucher BA, Fabian TC. Candida sp. isolated from bronchoalveolar lavage: clinical significance in critically ill trauma patients. Intensive Care Med. 2006;32(4):599–603.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas Health Science Center at Houston, 6431 Fannin St, MSB 2.112, Houston, TX, 77030, USA

    Ahmed Al Hammadi & Luis Ostrosky-Zeichner

Authors
  1. Ahmed Al Hammadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luis Ostrosky-Zeichner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahmed Al Hammadi.

Ethics declarations

Conflict of Interest

Ahmed Al Hammadi declares that he has no conflict of interest.

Luis Ostrosky-Zeichner has received grants and consulting or speaking fees from Pfizer, Astellas, Merck, Gilead, T2 Biosystems, Associates of Cape Cod, Scynexis, and Cidara.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Epidemiology of Fungal Infections

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Al Hammadi, A., Ostrosky-Zeichner, L. Epidemiology and Management of Candidiasis in Solid Organ Transplant Recipients. Curr Fungal Infect Rep 10, 147–152 (2016). https://doi.org/10.1007/s12281-016-0269-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12281-016-0269-y

Keywords

Search

Navigation